Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
NEW YORK (Reuters Health) – Brachytherapy is a viable option for prostate cancer patients 60 and younger, the authors of a new report in BJUI conclude. “Prostate cancer…
NEW YORK (Reuters Health) – New research does not support the routine use of hematopoietic stem cell transplantation (HSCT) in infants with acute lymphoblastic leukemia (ALL) with mixed…
NEW YORK (Reuters Health) – Putting patients on dialysis before they’re symptomatic offers no survival benefit; on the contrary, it may increase their risk of death, according to…
NEW YORK (Reuters Health) – Patients with acute migraine who find sumatriptan ineffective may have a better response to rizatriptan, according to a study reported in Cephalalgia online…
NEW YORK (Reuters Health) – For women of normal weight or moderate overweight who develop gestational diabetes late in pregnancy, treatment with metformin may be a suitable alternative…
NEW YORK (Reuters Health) – Augmenting antipsychotic treatment with a biologically active natural product, L-theanine, improves symptoms in patients with schizophrenia or schizoaffective disorder, Israeli investigators have shown…
NEW YORK (Reuters Health) – HIV patients whose regimen includes efavirenz and who experience CNS side effects such as insomnia and nervousness may benefit from a switch to…
NEW YORK (Reuters Health) – Hydroxychloroquine may reduce the heightened risk of cardiovascular disease in patients with rheumatoid arthritis. Use of hydroxychloroquine to treat rheumatoid arthritis is associated…
NEW YORK (Reuters Health) – The management of heart failure guided by an individualized target level of N-terminal pro-B-type natriuretic peptide (NT-proBNP) doesn’t lead to clinically significant improvements…
NEW YORK (Reuters Health) – The IL-6 receptor-blocking monoclonal antibody tocilizumab inhibits joint damage in patients with rheumatoid arthritis that is not adequately controlled with methotrexate, according to…
